Odontogenic Keratocysts: Causes, Symptoms, and Treatment

Odontogenic keratocysts are slow-growing, fluid-filled lesions that develop in the jawbone from remnants of the dental lamina, the tissue involved in tooth formation. They often grow silently for months or years before causing noticeable symptoms, which means many are discovered by accident on routine dental X-rays. What makes them stand apart from ordinary jaw cysts is their stubborn tendency to come back after removal, driven in part by genetic changes in a signaling pathway that controls cell growth. Treatment usually involves surgery, but the specific approach depends on the size, location, and whether the cyst has recurred before.

What Causes an Odontogenic Keratocyst

OKCs arise from small clusters of epithelial cells left over from the dental lamina, the embryonic tissue that gives rise to teeth. These leftover cell nests normally sit dormant in the jawbone, but something triggers them to start proliferating and forming a cyst lined with a distinctive keratinized epithelium. The molecular trigger that has drawn the most research attention is the PTCH gene, which encodes a protein in the Hedgehog signaling pathway. In normal cells, PTCH acts as a brake on cell proliferation. When PTCH is mutated, that brake fails, and cells can divide unchecked. Research has identified PTCH mutations in some OKCs that would produce truncated, nonfunctional proteins, resulting in loss of normal cell-cycle control.¹

These PTCH mutations can occur sporadically in a single cyst, or they can be inherited as part of a genetic syndrome. Either way, the underlying biology is similar: the Hedgehog pathway is overactive, pushing cells to grow when they should not be growing. This molecular behavior is one reason OKCs have been treated with more suspicion than other jaw cysts, and it also explains why targeted drug therapies are being explored.

The Cyst-Versus-Tumor Debate

OKCs have had an identity crisis in the pathology world. In 2005, the World Health Organization reclassified them as “keratocystic odontogenic tumors,” reflecting the view that their aggressive growth pattern and genetic alterations made them more tumor-like than cyst-like. Then in 2017, the WHO reversed course and reclassified them back as cysts.² If you come across older literature calling them KCOTs (keratocystic odontogenic tumors), it is referring to the same entity.

The reclassification matters more than it might seem. Calling something a tumor influences how aggressively surgeons treat it and how insurers cover the procedure. Neither label is entirely satisfying: OKCs clearly behave more aggressively than ordinary cysts, but they lack several hallmarks of true neoplasms. In practice, most oral surgeons treat OKCs with a healthy respect for their tendency to recur, regardless of which label is in vogue.

Symptoms and How OKCs Are Found

The frustrating thing about OKCs is that they tend to grow quietly. They typically appear in the back of the lower jaw, especially near the molars and the ramus (the vertical portion behind the wisdom teeth), and can expand considerably before producing any noticeable symptom.³ One characteristic of OKCs is their preference for growing lengthwise through the marrow space of the bone rather than ballooning outward. This means the jaw may not visibly swell until the cyst is already quite large.⁴

When symptoms do appear, they can include:

• Dull aching: a vague, low-grade pain in the jaw that may come and go
• Swelling: usually a firm, non-tender enlargement along the jawline or inside the mouth
• Loose teeth: teeth adjacent to the cyst may become mobile as bone support is eroded
• Numbness: if the cyst presses on the inferior alveolar nerve, the lower lip or chin on that side can feel tingly or numb
• Foul taste or drainage: if the cyst becomes secondarily infected or ruptures into the mouth

Many OKCs, however, are caught before any of those symptoms develop. A dentist notices a dark area on a panoramic X-ray taken for unrelated reasons, and the investigation begins from there.

What OKCs Look Like on Imaging

On a standard panoramic dental radiograph, an OKC appears as a well-defined dark (radiolucent) area with a thin white (sclerotic) border. About 70% of the time the lesion looks like a single chamber; in roughly 30% of cases, internal dividing walls create a multilocular appearance, especially in larger cysts.⁵ A CT scan comparing different jaw lesions found multilocular patterns in about 30% of OKCs, compared with over 60% of ameloblastomas, helping radiologists distinguish between the two.⁶

An important detail that does not always show up on plain radiographs: cortical bone perforation. Despite looking well-contained on a two-dimensional X-ray, studies report that the outer shell of bone has been breached in anywhere from 39 to 51% of OKCs when surgeons get a direct look during the operation.⁵ CT scans can also reveal satellite (daughter) cysts adjacent to the main lesion, particularly in large OKCs, which is relevant to surgical planning because leaving a satellite cyst behind sets the stage for recurrence.

Getting a Definitive Diagnosis

Imaging can raise suspicion, but only microscopic examination of tissue confirms an OKC. The hallmark features under the microscope are a thin, uniform epithelial lining with a corrugated parakeratinized surface and a distinctive palisaded basal cell layer. A large retrospective histopathological study found that 95% of OKCs displayed true parakeratinization, with the basal cells showing a reversed polarity pattern in 60% of cases. Satellite cysts were identified in about 9% of specimens.⁷ A study of 177 cases from Brazil documented additional features including epithelial lining thickening in nearly half of cases, daughter cysts in about 8%, and occasional focal orthokeratinization.⁸

Before surgery, a fine-needle aspiration biopsy can offer useful clues. Drawing out the cyst fluid with a needle and analyzing it for keratin-producing cells allows the surgeon to plan the operation more appropriately. One study found that combining fine-needle aspiration with staining for a specific keratin marker (cytokeratin 10) was 100% accurate in distinguishing OKCs from non-keratinizing jaw cysts.⁹ Knowing you are dealing with an OKC before the scalpel touches bone allows the surgical team to use adjunctive measures aimed at reducing recurrence, rather than finding out afterward and wondering whether the approach was aggressive enough.

Surgical Treatment Options

Surgery is the primary treatment for OKCs. The challenge is not just removing the cyst but doing so in a way that minimizes the chance it comes back. Several approaches exist, and the choice depends on the cyst’s size, location, relationship to nearby nerves and teeth, whether it has recurred before, and how aggressively the surgeon and patient want to treat it.

Enucleation With Adjunctive Therapy

Enucleation means carefully shelling the entire cyst out of the bone in one piece. Because the OKC lining is notoriously thin and fragile, it can tear during removal, leaving behind microscopic fragments that seed a recurrence. To address this, many surgeons apply Carnoy’s solution (a chemical fixative) to the bony walls of the cavity immediately after enucleation. A study of 30 biopsy-confirmed OKCs treated with enucleation followed by freshly prepared Carnoy’s solution reported a recurrence rate of about 6%.¹⁰ Carnoy’s solution chemically destroys any residual epithelial cells clinging to the bone surface, but it must be used carefully near nerves because it can damage them too.

Another adjunctive approach gaining attention is topical 5-fluorouracil (5-FU), a drug commonly used in cancer treatment, applied directly to the cyst cavity after enucleation. One study reported a significantly lower rate of inferior alveolar nerve numbness with 5-FU compared with Carnoy’s solution, which is an advantage when the cyst sits right next to the nerve.¹¹

Decompression and Marsupialization

For very large OKCs, or when the cyst is dangerously close to vital structures, surgeons sometimes create a small opening (a stoma) in the cyst wall and place a tube or stent to keep it open. This allows the cyst to drain continuously, gradually shrinking it over months. Once the cyst has decreased enough in size, a second surgery removes the residual lining. The advantage is preserving bone and nearby structures. The downside is patience: the process can take six months to over a year, and it requires the patient to irrigate the opening regularly.

There is some evidence that decompression may alter the biology of the cyst lining. A study examining stem-cell markers in OKC tissue found that the marker SOX2 was expressed in 90% of decompressed OKCs, compared with 80% of both primary and recurrent OKCs. Meanwhile, another stemness marker, OCT4, was detected in 10% of primary and 20% of recurrent OKCs, but showed no positivity at all in decompressed cases.¹² What exactly that means for recurrence risk is still being studied, but it suggests that the decompression process changes the character of the remaining cyst lining.

Radical Resection

In some situations, removing a margin of healthy bone along with the cyst is warranted. A systematic review of clinical indications for radical resection found that common reasons included multilocular cysts, large lesions exceeding 5 centimeters, multiple recurrences with or without cortical bone perforation, and, rarely, malignant transformation. In the cases reviewed, segmental mandibulectomy (removing a full-thickness segment of the jawbone) was performed in 131 cases, while marginal mandibulectomy (shaving the involved portion without cutting through the full jaw) was used in 87 cases.¹³ Resection is the most aggressive option and essentially eliminates local recurrence, but it comes at the cost of jaw continuity, requiring reconstruction with bone grafts or metal plates and prolonged rehabilitation.

Recurrence and Long-Term Monitoring

Recurrence rates for OKCs vary widely in the literature, from under 5% with aggressive treatment protocols to over 50% with simple enucleation alone over long follow-up periods. The fragile cyst lining, daughter cysts in surrounding bone, and residual dental lamina cell nests all contribute to the problem. Recurrences can appear years or even more than a decade after the original surgery, which is why long-term imaging follow-up is standard.

Researchers have explored whether molecular markers can predict which OKCs are more likely to come back. A study measuring cell-proliferation markers found that levels of both Ki-67 (a protein marking actively dividing cells) and AgNOR counts were significantly higher in OKCs that later recurred compared with those that did not.¹⁴ If validated in larger studies, such markers could help surgeons decide upfront whether a more aggressive surgical approach is warranted for a given patient.

The Gorlin-Goltz Syndrome Connection

While most OKCs are isolated, sporadic events, some appear as part of Gorlin-Goltz syndrome (also called nevoid basal cell carcinoma syndrome), an inherited condition caused by germline mutations in the PTCH gene. People with this syndrome develop multiple OKCs, often at a young age, along with a constellation of other features. The classic triad includes multiple basal cell skin cancers, multiple jaw keratocysts, and skeletal abnormalities.¹⁵ Other hallmarks include calcification of a brain membrane called the falx cerebri, rib anomalies like bifid ribs, pits on the palms and soles, and wide-set eyes.¹⁶

Jaw cysts are often the earliest sign of the syndrome, sometimes appearing in the first decade of life before skin cancers develop. A routine panoramic X-ray in a teenager showing multiple cystic lesions should prompt the clinician to consider Gorlin-Goltz syndrome and examine for additional features.¹⁷ Managing OKCs in these patients is particularly challenging because new cysts keep forming throughout life, and repeated surgeries can cause cumulative damage to the jaw. This is one of the main clinical scenarios driving interest in non-surgical therapies.

Hedgehog Pathway Inhibitors

Because OKCs are driven by overactive Hedgehog signaling, drugs that block this pathway are a logical therapeutic target. Vismodegib, originally developed to treat advanced basal cell carcinoma, has been tested in patients with Gorlin-Goltz syndrome who had existing OKCs. In a clinical trial, six patients with Gorlin-Goltz syndrome received vismodegib daily for an average of 18 months. Four experienced measurable shrinkage of their cysts, and two had no change. On average, the longest diameter of their OKCs was reduced by about half.¹⁸ No existing cysts enlarged, and no new ones appeared during treatment. Other reports have described near-complete regression of syndrome-associated OKCs with vismodegib, potentially making subsequent surgical procedures less extensive.¹⁹

Laboratory research continues to explore how Hedgehog inhibition works at the cellular level. A recent study using the same drug (known by its research name GDC-0449) on fibroblasts isolated from OKC tissue found that it reduced the cells’ ability to migrate, invade, and stimulate bone breakdown, while promoting bone formation.²⁰ This dual effect, tamping down destructive behavior while encouraging bone repair, is exactly what you would want in a jaw lesion. Vismodegib does carry side effects, including muscle cramps, hair loss, and taste disturbance, and most patients cannot take it indefinitely. For now, it is primarily considered for syndromic patients with recurring or inoperable cysts rather than for routine sporadic OKCs.

OKCs in Children and Adolescents

OKCs can occur in children, though they are less common than in adults. When they do appear in young patients, the diagnosis tends to come late because jaw cysts are not high on most pediatricians’ or general dentists’ radar in this age group. A review of pediatric OKCs emphasized that late presentation, combined with the cyst’s destructive growth and high recurrence rate, makes early detection particularly important.²¹ The review recommended follow-up imaging every six months after treatment and multidisciplinary team management when Gorlin-Goltz syndrome is suspected.

A long-term retrospective analysis of pediatric jaw cysts over 18 years found that OKCs accounted for about 9% of cases, with the posterior mandible being the most common location. Among pediatric patients with odontogenic cysts overall, 72% needed at least one permanent tooth extracted as part of treatment, and the need for extraction was significantly associated with larger cyst size. The recurrence rate across all pediatric jaw cysts was low at about 3%, though the follow-up averaged only about four years, and OKC recurrences are known to appear later than that.²² Treatment decisions in children carry extra weight because aggressive surgery can interfere with jaw growth and developing permanent teeth, yet conservative treatment risks recurrence and a second operation.

Malignant Transformation

One of the rarer but more alarming possibilities with an OKC is transformation into squamous cell carcinoma within the bone. Case reports have documented OKCs whose lining develops dysplastic changes, including abnormal cell shapes, increased nuclear staining, and unusual mitotic figures, eventually giving rise to invasive cancer. One documented case showed the classic OKC lining transitioning into islands of well-differentiated squamous cell carcinoma with keratin pearl formation.²³ This outcome is exceedingly rare and is considered one of the recognized indications for radical resection. For the vast majority of patients, an OKC remains a benign lesion, but the possibility of malignant change underscores why these cysts should not be dismissed or left unmonitored even after apparently successful treatment.